LXEO·Nasdaq·US

Lexeo Therapeutics

Lexeo Therapeutics is a clinical stage genetic medicine company focused on cardiovascular diseases. It is advancing gene therapy candidates aimed at underlying genetic causes of conditions including Friedreich ataxia cardiomyopathy and PKP2 arrhythmogenic cardiomyopathy, and it retains exclusive worldwide development and commercialization rights to all of its product candidates and programs.

Source: SEC 10-K Mar 30, 2026

Create free account

Thematic Position

LXEO

Healthcare Innovation

Gene Therapy & EditingLeader

Relationship Groups

Partners1

Competitors6

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

2 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

export controlsanctionlicensing requirement

U.S. export control and sanctions regimes may require licenses for exporting Lexeo product candidates

SEC 10-QMay 11, 2026

The full regulatory passage is part of the Pro plan.

4 more · Regulatory and geopolitical insights are part of the Pro plan.